Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker(Herlev Hospital), Robert J. Glynn(Brigham and Women's Hospital), Tamás Forster(Brigham and Women's Hospital), Hiroaki Shimokawa(Tohoku University), Jan H. Cornel(Brigham and Women's Hospital), Hisao Ogawa(Kumamoto University Hospital), Jacques Genest(McGill University Health Centre), Wolfgang Köenig(German Centre for Cardiovascular Research), Francisco Antônio Helfenstein Fonseca(Universidade Federal de São Paulo), Marcus Flather(Norfolk and Norwich University Hospital), Jean MacFadyen(Brigham and Women's Hospital), Christie M. Ballantyne(Baylor College of Medicine), Renata Cífková(Brigham and Women's Hospital), José Carlos Nicolau(Hospital São Paulo), Roland P.T. Troquay(Brigham and Women's Hospital), L Vida-Simiti(Brigham and Women's Hospital), John J.P. Kastelein(QRx Pharma (United States)), Zhanna Kobalava(Peoples' Friendship University of Russia), Tom Thurén(Novartis (Switzerland)), Daniel Pella(Brigham and Women's Hospital), Paulo R.F. Rossi(Brigham and Women's Hospital), Mikael Dellborg(Brigham and Women's Hospital), William H. Chang(Brigham and Women's Hospital), Prem Pais(Brigham and Women's Hospital), Peter Libby(Brigham and Women's Hospital), Alberto Lorenzatti(Brigham and Women's Hospital), Stefan D. Anker(Bayer (Germany))
Cited by 9,074
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
|New England Journal of Medicine|2002|3.6k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k